Dr Reddy’s Laboratories Limited is a drug manufacturing major in Indian Drug market. It is a large-cap company. Dr Reddy’s share price movement affect the benchmark index because it belongs to Nifty 50 group of companies.
Dr Reddy’s Share Price Graph
Dr Reddy’s Laboratories Limited was incorporated in 1984 starting its operation in the API (Active pharmaceutical ingredient) segment with a single drug and made the first shipment of 60 tonnes to Germany (then West Germany) in 1986.
Currently it is counted among the top global players in API segment. It runs its business in more than 100 countries across the world. Today it has subsidiaries in UK, US, Russia, Germany and Brazil. Also it has joint ventures running in China, South Africa and Australia. In addition Dr Reddy’s has representative offices in 10 countries and third party distributors appointed in 21 more countries. Outside Japan, it is the first company in Asia to be listed in NYSE (New York Stock Exchange).
The company is the largest company operating in CPS (custom pharmaceutical service) segment in India. There are many drugs manufactured by Dr Reddy’s which are almost household names in India like Omez, Stamlo, Nise Ciprolet among many others. In 2009 Dr Reddy’s made strategic alliance with GSK (Glaxo SmithKline) to develop and market GSK’s selective drugs outside India in the emerging markets of world.
Dr reddy’s has the following facilities for manufacture and development of drugs. They are
- 3 technological development centres in which two are in Hyderabad and one in UK
- 6 USFDA approved plants in India
- 1 USFDA approved plant in UK
- 1 USFDA approved plant in Mexico
- 1 Cytotoxin manufacturing unit
The company has received many awards for excellence in drug manufacturing field.
Company Financials – Dr Reddy’s share price is Rs 2654 (as on 19.06.17, 11.53 hrs.) in BSE. As per latest data, the standalone basis P/E is 32.07 versus average industry PE of 28.41, EPS is Rs 83.49. Market cap is Rs 44,383 crores. The face value of a share is Rs 5.
You can also visit, information on other companies.